Should I Buy ANEB? ANEB 2026 Analysis

Should You Buy Anebulo Pharmaceuticals Inc (ANEB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.500

1 Day change

-39.09%

52 Week Range

3.420

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: the dominant trend is still bearish (SMA_200 > SMA_20 > SMA_5) and there are no Intellectia buy signals today.
Short-term momentum is trying to improve (MACD histogram positive and expanding), but price is still below the pivot (0.971) and upside levels (R1 1.093) are overhead.
With no revenue, widening losses (2026/Q1), and an upcoming earnings event (2026-02-12 AH), the setup is more “high-risk event/volatility” than a clean entry.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bearish structure (SMA_200 > SMA_20 > SMA_5) indicates the broader downtrend remains intact.
Momentum: MACD histogram at 0.0282 and positively expanding suggests a potential short-term rebound attempt.
RSI: RSI_6 at 41.835 (neutral-to-weak) shows no strong buying pressure yet.
Key levels: Pivot 0.971 (price ~0.95 is below it). Support S1 0.849 then S2 0.774; Resistance R1 1.093 then R2 1.169.
Pattern-based odds provided: modest edge at best (next day +0.63% / next week -0.51% / next month +0.41%), not supportive of an urgent buy.

Positive Catalysts

- Completed tender offer repurchasing shares at $3.50 (reduces float modestly and increases shareholder concentration).
- Strategic focus on an IV formulation of selonabant for pediatric acute cannabis-induced toxicity, framed as a path to potentially expedite approval.
- Earnings date (2026-02-12 After Hours) can act as a volatility catalyst if updates are unexpectedly positive.

Neutral/Negative Catalysts

- Price trading far below the recent tender price ($3.50 vs ~0.95 pre-market) signals weak market confidence and/or changed expectations.
- No meaningful hedge fund/insider trading trend noted recently (neutral), so there’s no “smart money” accumulation signal in the provided data.
- Bearish moving-average stack suggests rallies may face overhead supply.
- Earnings (2026-02-12 AH) is a near-term binary risk event with no supportive pre-signal from Intellectia modules.

Financial Performance

Latest quarter: 2026/Q1.
Revenue: 0 (no operating revenue; 0.00% YoY change).
Net income: -2,158,354 (down -1.93% YoY; loss widened).
EPS: -0.05 (down -37.50% YoY).
Overall: financials do not show improving growth/earnings power yet, making the stock more catalyst-dependent than fundamentals-driven.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there’s no identifiable recent Wall Street trend to lean on.
Wall Street-style pros/cons view (based on provided info):
- Pros: clearer clinical/regulatory focus (IV selonabant in pediatric acute cannabis toxicity) and some capital management via tender.
- Cons: no revenue, ongoing losses, weak technical trend, and no confirmed buy-side signal from the provided trading/sentiment tools.
Politicians/influential figures: No recent congress trading data available (no evidence of notable political buying/selling in the last 90 days).

Analyst Rating

Wall Street analysts forecast ANEB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANEB is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 0.821

Low

Averages

High

Current: 0.821

Low

Averages

High

Maxim

Michael Okunewitch

Buy

Hold

downgrade

AI Analysis

2025-07-23

Reason

Maxim

Michael Okunewitch

Price Target

AI Analysis

2025-07-23

downgrade

Buy

Hold

Reason

Maxim analyst Michael Okunewitch downgraded Anebulo Pharmaceuticals to Hold from Buy.

Maxim

Buy

downgrade

$6 -> $3

2025-05-15

Reason

Maxim

Price Target

$6 -> $3

2025-05-15

downgrade

Buy

Reason

Maxim lowered the firm's price target on Anebulo Pharmaceuticals to $3 from $6 and keeps a Buy rating on the shares after its Q3 results. The company is prioritizing the advancement of IV selonbant into a Phase 1 SAD study in healthy adults, and the firm adjusting its price target to reflect this pivot, though Maxim remains positive on Anebulo given the unmet need in severe cannabis toxicity, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANEB

Unlock Now

ANEB Should I Buy

ANEB Should I Buy

Should You Buy Anebulo Pharmaceuticals Inc (ANEB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch